Joyce P.Y. Mak

Joyce P.Y. Mak

Auto-generated profile, based on publicly available information

Joyce P.Y. Mak

Division of Life Science, Center for Cancer Research, and State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JMJoyce P.Y. Mak
Joyce P.Y. Mak
HMHoi Tang Ma
Hoi Tang Ma
RPRandy Yat Choi Poon
Randy Yat Choi Poon
PARP inhibitors have emerged as effective chemotherapeutic agents for BRCA1/BRCA2-deficient cancers. Another DNA damage response protein, ATM, is also increasingly being recognized as a target for synthetic lethality with PARP inhibitors. As ATM functions in both cell cycle arrest and DNA repair after DNA damage, how cells respond to inhibition of ATM and PARP1 is yet to be defined precisely. We found that loss of ATM function, either in an ATM-deficient background or after treatment with ATM inhibitors (KU-60019 or AZD0156), results in spontaneous DNA damage and an increase in PARylation. When PARP1 is also deleted or inhibited with inhibitors (olaparib or veliparib), the massive increase in DNA damage activates the G2 DNA damage checkpoint kinase cascade involving ATR, CHK1/2, and WEE1. Our data indicated that the role of ATM in DNA repair is critical for the synergism with PARP inhibitors. Bypass of the G2 DNA damage checkpoint in the absence of ATM functions occurs only after a delay. The relative insensitivity of PARP1-deficient cells to PARP inhibitors suggested that other PARP isoforms played a relatively minor role in comparison with PARP1 in synergism with ATMi. As deletion of PARP1 also increased sensitivity to ATM inhibitors, trapping of PARP1 on DNA may not be the only mechanism involved in the synergism between PARP1 and ATM inhibition. Collectively, these studies provide a mechanistic foundation for therapies targeting ATM and PARP1.

21 May 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
JMJoyce P.Y. Mak
Joyce P.Y. Mak
WMWing Yu Man
Wing Yu Man
JCJeremy P.H. Chow
Jeremy P.H. Chow
HMHoi Tang Ma
Hoi Tang Ma
RPRandy Yat Choi Poon
Randy Yat Choi Poon
Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells

20 March 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
JLJingjing Li
Jingjing Li
MHMyung Jin Hong
Myung Jin Hong
JCJeremy P.H. Chow
Jeremy P.H. Chow
WMWing Yu Man
Wing Yu Man
JMJoyce P.Y. Mak
Joyce P.Y. Mak
RPRandy Yat Choi Poon
Randy Yat Choi Poon
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe

25 September 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
JMJoyce P.Y. Mak
Joyce P.Y. Mak
WMWing Yu Man
Wing Yu Man
HMHoi Tang Ma
Hoi Tang Ma
RPRandy Yat Choi Poon
Randy Yat Choi Poon
The ATR–CHK1–WEE1 kinase cascade’s functions in the DNA damage checkpoints are well established. Moreover, its roles in the unperturbed cell cycle are also increasingly being recognized. In this connection, a number of small-molecule inhibitors of ATR, CHK1, and WEE1 are being evaluated in clinical trials. Understanding precisely how cells respond to different concentrations of inhibitors is therefore of paramount importance and has broad clinical implications. Here we present evidence that in the absence of DNA damage, pharmacological inactivation of ATR was less effective in inducing mitotic catastrophe than inhibition of WEE1 and CHK1. Small-molecule inhibitors of CHK1 (AZD7762) or WEE1 (MK-1775) induced mitotic catastrophe, as characterized by dephosphorylation of CDK1Tyr15, phosphorylation of histone H3Ser10, and apoptosis. Unexpectedly, partial inhibition of WEE1 and CHK1 had the opposite effect of accelerating the cell cycle without inducing apoptosis, thereby increasing the overall cell proliferation. This was also corroborated by the finding that cell proliferation was enhanced by kinase-inactive versions of WEE1. We demonstrated that these potential limitations of the inhibitors could be overcome by targeting more than one components of the ATR–CHK1–WEE1 simultaneously. These observations reveal insights into the complex responses to pharmacological inactivation of the ATR–CHK1–WEE1 axis.

9 April 2025 in Journal of Cell Biology
Verified
Journal Article
Open access
ACAdrijana Crncec
Adrijana Crncec
HLHo Wai Lau
Ho Wai Lau
LNLau Yan Ng
Lau Yan Ng
HMHoi Tang Ma
Hoi Tang Ma
JMJoyce P.Y. Mak
Joyce P.Y. Mak
RPRandy Yat Choi Poon
Randy Yat Choi Poon
Cyclins and cyclin-dependent kinases (CDKs) orchestrate key events in the cell cycle. However, the uniqueness of individual mitotic cyclins has been a long-standing puzzle. By rapidly removing cyclins in G2 human cells, we found that deficiency of B-type cyclins attenuates mitotic onset and uncouples the G2–M kinase network from mitosis, resulting in sustained activation of PLK1 and cyclin A–CDK1. This culminates in mitotic slippage without completing nuclear envelope breakdown. Remarkably, elevating cyclin A several-fold above its endogenous level is adequate to restore mitosis, allowing cells to survive without B-type cyclins. In contrast, cyclin A is rate-limiting but not essential for G2–M due to compensation by endogenous cyclin B1–CDK2, a non-canonical pair. These findings challenge the traditional indispensable roles of different cyclins and highlight their plasticity. Due to the high malleability of the A- and B-type cyclins, cancer cells may be able to place different weights on different cyclins, while maintaining sufficient CDK activities for successful mitosis.

18 November 2013 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
WMWing Yu Man
Wing Yu Man
JMJoyce P.Y. Mak
Joyce P.Y. Mak
RPRandy Yat Choi Poon
Randy Yat Choi Poon
Dovitinib (TKI258; formerly CHIR-258) is an orally bioavailable inhibitor of multiple receptor tyrosine kinases. Interestingly, Dovitinib triggered a G2/M arrest in cancer cell lines from diverse origins including HeLa, nasopharyngeal carcinoma, and hepatocellular carcinoma. Single-cell analysis revealed that Dovitinib promoted a delay in mitotic exit in a subset of cells, causing the cells to undergo mitotic slippage. Higher concentrations of Dovitinib induced a G2 arrest similar to the G2 DNA damage checkpoint. In support of this, DNA damage was triggered by Dovitinib as revealed by γ-H2AX and comet assays. The mitotic kinase CDK1 was found to be inactivated by phosphorylation in the presence of Dovitinib. Furthermore, the G2 arrest could be overcome by abrogation of the G2 DNA damage checkpoint using small molecule inhibitors of CHK1 and WEE1. Finally, Dovitinib-mediated G2 cell cycle arrest and subsequent cell death could be promoted after DNA damage repair was disrupted by inhibitors of poly(ADP-ribose) polymerases. These results are consistent with the recent finding that Dovitinib can also target topoisomerases. Collectively, these results suggest additional directions for use of Dovitinib, in particular with agents that target the DNA damage checkpoint.